tirzepatide launch date Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial FDA approves tirzepatide, Eli Lilly's

The resulting death of pericytes leaves the microvasculature continuously constricted, leading to microcirculatory failure and long-term cerebral hypoperfusion due to the contractile apparatus remaining in rigor upon pericyte death, thus reducing capillary diameter [94, 104]

Re-rate day 14

Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

That said, if youre on a GLP-1, it wouldnt hurt to let the PET center know, so when theyre reading the scan, they can have that in mind

Until more information becomes available and out of an abundance of caution, alternative medications should be used while nursing

Those that do often require prior authorization, step therapy, or documentation of a BMI above a certain threshold plus at least one weight-related comorbidity